source
- Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potentialCurium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…
- Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cutsAngus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…